Meridian Bioscience

Meridian Bioscience Gross Profit

The Gross Profit of Meridian Bioscience (VIVO) as of Nov 3, 2026 is 188.36 M USD. In the previous year, Gross Profit was 201.15 M USD — a change of -6.36% (lower).

Gross Profit

188.36 MUSD

YoY

-6.36%

Last updated:

Gross Profit of Meridian Bioscience is 2022 188.36 M USD. Gross Profit of Meridian Bioscience was 2021 201.15 M USD. It decreases by -6.36% lower compared to the previous year.

The Meridian Bioscience Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2015
121.90 M USD
Jan 1, 2016
127.20 M USD
Jan 1, 2017
124.30 M USD
Jan 1, 2018
131.00 M USD
Jan 1, 2019
118.70 M USD
Jan 1, 2020
156.20 M USD
Jan 1, 2021
201.15 M USD
Jan 1, 2022
188.36 M USD
The Meridian Bioscience Gross Profit history
YEARGross ProfitYoY
188.36 MUSD-6.36%
201.15 MUSD+28.78%
156.20 MUSD+31.59%
118.70 MUSD-9.39%
131.00 MUSD+5.39%
124.30 MUSD-2.28%
127.20 MUSD+4.35%
121.90 MUSD+4.01%
117.20 MUSD-3.14%
121.00 MUSD+11.01%
109.00 MUSD+10.77%
98.40 MUSD+10.94%
88.70 MUSD-4.00%
92.40 MUSD+6.82%
86.50 MUSD+15.49%
74.90 MUSD+15.77%
64.70 MUSD+17.85%
54.90 MUSD+20.13%
45.70 MUSD+19.32%
38.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Revenue

Meridian Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
213.60 M USD
44.70 M USD
23.80 M USD
Jan 1, 2019
201.00 M USD
38.90 M USD
24.40 M USD
Jan 1, 2020
253.70 M USD
68.00 M USD
46.20 M USD
Jan 1, 2021
317.90 M USD
101.83 M USD
71.41 M USD
Jan 1, 2022
333.02 M USD
75.60 M USD
42.46 M USD
Jan 1, 2023 (e)
294.11 M USD
46.97 M USD
37.34 M USD
Jan 1, 2024 (e)
302.36 M USD
32.45 M USD
26.22 M USD
Jan 1, 2025 (e)
300.53 M USD
22.86 M USD
18.78 M USD

Meridian Bioscience Margins

Meridian Bioscience stock margins

The Meridian Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Meridian Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Meridian Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
61.33 %
20.93 %
11.14 %
Jan 1, 2019
59.05 %
19.35 %
12.14 %
Jan 1, 2020
61.57 %
26.80 %
18.21 %
Jan 1, 2021
63.27 %
32.03 %
22.46 %
Jan 1, 2022
56.56 %
22.70 %
12.75 %
Jan 1, 2023 (e)
56.56 %
15.97 %
12.70 %
Jan 1, 2024 (e)
56.56 %
10.73 %
8.67 %
Jan 1, 2025 (e)
56.56 %
7.61 %
6.25 %

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Gross Profit of Meridian Bioscience is 188.36 M USD in 2022.

Gross Profit of Meridian Bioscience changed from 201.15 M USD to 188.36 M USD, representing a -6.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Meridian Bioscience

All Key Metrics — Meridian Bioscience